CN103784934A - Pharmaceutical composition for preventing and curing acute myocardial infarction and application thereof - Google Patents
Pharmaceutical composition for preventing and curing acute myocardial infarction and application thereof Download PDFInfo
- Publication number
- CN103784934A CN103784934A CN201410090935.3A CN201410090935A CN103784934A CN 103784934 A CN103784934 A CN 103784934A CN 201410090935 A CN201410090935 A CN 201410090935A CN 103784934 A CN103784934 A CN 103784934A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- myocardial infarction
- acute myocardial
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 206010000891 acute myocardial infarction Diseases 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 12
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 5
- 230000000302 ischemic effect Effects 0.000 abstract description 4
- 244000105624 Arachis hypogaea Species 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 230000001154 acute effect Effects 0.000 abstract description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 abstract description 2
- 240000005528 Arctium lappa Species 0.000 abstract description 2
- 235000003130 Arctium lappa Nutrition 0.000 abstract description 2
- 241000209140 Triticum Species 0.000 abstract description 2
- 244000273928 Zingiber officinale Species 0.000 abstract description 2
- 235000006886 Zingiber officinale Nutrition 0.000 abstract description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 235000008397 ginger Nutrition 0.000 abstract description 2
- 230000003859 lipid peroxidation Effects 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 230000010412 perfusion Effects 0.000 abstract description 2
- 230000002107 myocardial effect Effects 0.000 abstract 2
- 235000017060 Arachis glabrata Nutrition 0.000 abstract 1
- 235000018262 Arachis monticola Nutrition 0.000 abstract 1
- 235000008078 Arctium minus Nutrition 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 235000021307 Triticum Nutrition 0.000 abstract 1
- 235000020232 peanut Nutrition 0.000 abstract 1
- 238000005502 peroxidation Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 17
- 239000012567 medical material Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 210000004165 myocardium Anatomy 0.000 description 9
- 102000019197 Superoxide Dismutase Human genes 0.000 description 5
- 108010012715 Superoxide dismutase Proteins 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 4
- 230000007574 infarction Effects 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 2
- 229960002327 chloral hydrate Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 239000001841 zingiber officinale Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for preventing and curing acute myocardial infarction and an application thereof. The pharmaceutical composition is prepared from the following traditional Chinese medicine raw materials of, by weight, 42-60 parts of peanut shells, 42-60 parts of light wheat, 16-25 parts of fried cassia, 16-25 parts of dried ginger and 25-38 parts of burdock. The pharmaceutical composition can effectively eliminate oxygen free radicals, reduce free radicals damage factors, relieve lipid peroxidation reaction, reduce myocardial enzyme release, improve ischemic myocardial perfusion and have a positive protection effect on the heart, and is particularly suitable for preventing and curing acute ischemic myocardial infarction.
Description
Technical field
The invention belongs to Chinese medicine technical field, in particular to a kind of pharmaceutical composition and application thereof that prevents and treats acute myocardial infarction.
Background technology
Acute myocardial infarction is that coronary artery is acute, the caused myocardial necrosis of persistence hypoxic-ischemic.Clinically have a violent and lasting retrosternal pain more, has a rest and nitrate esters medicine can not be alleviated completely, increases and the variation of carrying out property electrocardiogram with serum enzyme activities, can complicated by arrhythmia, shock or heart failure, and often can threat to life.Primary disease is the most common America and Europe, and the U.S. approximately has 1,500,000 people that myocardial infarction occurs every year.China is obvious ascendant trend in recent years, annual new at least 50 ten thousand, now suffers from least 200 ten thousand.
Summary of the invention
The object of the invention is to improve on the basis of folk remedy, thereby a kind of pharmaceutical composition and application that prevents and treats acute myocardial infarction is provided.
The object of the present invention is achieved like this:
Prevent and treat a pharmaceutical composition for acute myocardial infarction, it is prepared from by the traditional Chinese medicinal material raw materials that comprises following weight portion: Pericarppium arachidis hypogaeae 42-60 part, Fructus Tritici Levis 42-60 part, stir-fry Semen Cassiae 16-25 part, Rhizoma Zingiberis 16-25 part, Fructus Arctii 25-38 part.
Preferably, the pharmaceutical composition of control acute myocardial infarction as above, it is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Pericarppium arachidis hypogaeae 48-53 part, Fructus Tritici Levis 48-53 part, stir-fry Semen Cassiae 18-22 part, Rhizoma Zingiberis 18-22 part, Fructus Arctii 30-32 part.
In a most preferred embodiment of the present invention, the pharmaceutical composition of control acute myocardial infarction as above is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: 50 parts of Pericarppium arachidis hypogaeaes, 50 parts of Fructus Tritici Levis, 20 parts of Semen Cassiae of stir-fry, 20 parts of Rhizoma Zingiberiss, 30 parts of Fructus Arctiis.
Find by a large amount of animal experiment research, pharmaceutical composition of the present invention is for the prevention effect highly significant of rat acute ischemic myocardial Infarction Model, therefore, second object of the present invention is to provide a kind of pharmaceutical applications, i.e. the application of aforementioned pharmaceutical compositions in the medicine of preparation control acute myocardial infarction.In pharmaceutical applications, this pharmaceutical composition can be prepared as oral formulations; Oral formulations wherein comprises oral liquid, tablet, capsule, granule.
The pharmaceutical composition the present invention relates to has strengthened the consumption of Fructus Tritici Levis, Rhizoma Zingiberis and Fructus Arctii on the basis of medical material conventional amount used; gomi herbs synergism; few and the effect of taste specially; can effectively remove oxygen-derived free radicals, reduce the free radical damageability factor, alleviate lipid peroxidation; reducing myocardium enzyme discharges; improve ischemic myocardium perfusion, heart is had to positive protective effect, be applicable to very much control acute myocardial infarction.
The specific embodiment
Be below specific embodiments of the invention, technical scheme of the present invention is described further, but protection scope of the present invention is not limited to these embodiment.Every do not deviate from the change of the present invention design or be equal to substitute include within protection scope of the present invention.
It should be noted that, the traditional Chinese medicinal material raw materials that the embodiment of the present invention adopts has following source: Pericarppium arachidis hypogaeae is selected the dry pod shell of pulse family Arachis plant Semen arachidis hypogaeae Arachis hypogaea L. fruit; Fructus Tritici Levis is selected the fruit of the dry frivolous lack of filling power of grass family Triticum plant Semen Tritici aestivi Triticum aestivum L.; Fry Semen Cassiae and select the dry mature seed of leguminous plant Semen Cassiae Cassia obtusifolia L., fry to micro-perfume (or spice); Rhizoma Zingiberis is selected the dry rhizome of zingiber Zingiber officinale Rosc.; Fructus Arctii is selected the dry mature fruit of feverfew Fructus Arctii Arctium lappa L..
Embodiment 1
Take Pericarppium arachidis hypogaeae 0.50kg, Fructus Tritici Levis 0.50kg, fry Semen Cassiae 0.20kg, Rhizoma Zingiberis 0.20kg and Fructus Arctii 0.30kg, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added water and covers powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 10 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 8 times of amounts of medical material, decoct 1h, getting twice decocting liquid merges, filter, be concentrated into every milliliter containing 2.5g crude drug amount, set to 0-5 ℃ of deepfreeze 24h, cold preservation liquid is filtered, obtain medicinal liquid.
Embodiment 2
Pericarppium arachidis hypogaeae 0.53kg, the Fructus Tritici Levis 0.50kg, stir-fry Semen Cassiae 0.25kg, Rhizoma Zingiberis 0.18kg and the Fructus Arctii 0.38kg that take recipe quantity, clean roguing, dries, and pulverizes; Again above-mentioned graininess medical material is added water and covers powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 8 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 8 times of amounts of medical material, decoct 1h, getting twice decocting liquid merges, filter, be concentrated into every milliliter containing 3g crude drug amount, set to 0-5 ℃ of deepfreeze 24h, cold preservation liquid is filtered, obtain medicinal liquid.
Embodiment 3
Take Pericarppium arachidis hypogaeae 0.42kg, Fructus Tritici Levis 0.60kg, fry Semen Cassiae 0.16kg, Rhizoma Zingiberis 0.25kg and Fructus Arctii 0.25kg, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added water and covers powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 8 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 6 times of amounts of medical material, decoct 1h, getting twice decocting liquid merges, filter, be concentrated into every milliliter containing 3g crude drug amount, set to 0-5 ℃ of deepfreeze 24h, cold preservation liquid is filtered, obtain medicinal liquid.
The effectiveness study of embodiment 4 medicine of the present invention to acute myocardial infarction rat model
36 of Wistar rats, SPF level, female half and half, body weight 250-300g, is divided into model control group, sham operated rats, treatment group by rat; Every group 12.With after 4% chloral hydrate intraperitoneal anesthesia, tracheal intubation, practices artificial respiration.Left side the 3rd, 4 intercostals are opened breast, cut off pericardium, expose cardiac muscle, and be placed under ramus descendens anterior arteriae coronariae sinistrae initial part the left crown anterior descending artery of 2 mm places ligation with circular noinvasive sewing needle 6/0 silk thread, obviously raise or T wave height is alarmmed, myocardium colour-darkening redness successfully indicates as ligation take ECG II ST-Segment.Sham operated rats is not ligation of threading.All rat oral gavage 4d in advance for the treatment of group, gavage medicine is medicinal liquid prepared by the embodiment of the present invention 1, administration concentration is 10mL/kg body weight, every day 1 time, after administration 30min on the 4th, carry out acute myocardial infarction operation by preceding method, the left crown anterior descending artery of Banded Rats.
After each group rat modeling success, 4% chloral hydrate intraperitoneal injection of anesthesia, ventral aorta blood sampling respectively after 6h, anticoagulant heparin, puts in refrigerated centrifuger, the centrifugal 10min of 3000 r/min, get supernatant,-20 ℃ of preservations, each group of rat plasma creatine kinase to be measured (CK) activity, detects superoxide dismutase (SOD), malonaldehyde (MDA) content in blood plasma.After taking blood, each modeling rat puts to death, take out rapidly heart, wash residual to the greatest extent blood with ice normal saline, blot and weigh with filter paper, be placed in-20 ℃ of freezing 15min, after 15min, heart crosscut is become to the uniform thin slice of 1-2mm thickness, be placed in pH 7.4 l% 2, 3, in 5-triphenyl tetrazolium chloride phosphate buffer, in 37 ℃ of dyeing 15 min, 4% formalin is fixed after 10 min, (infarcted myocardium is white in color to separate infarcted myocardium and normal myocardium, non-infarcted myocardium is kermesinus), weigh respectively, calculate infarcted myocardium and account for the percentage ratio of weight in wet base (%) whole-heartedly, it is myocardial infarction rate, infarction rate=Infarct area quality/quality × 100% whole-heartedly.
Result of the test by table 1 can find out, with sham operated rats comparison, model control group Plasma CK, MDA content obviously raise (
p< 0.05 or
p< 0.01); With model control group comparison, treatment group can obviously reduce CK content (
p< 0.01); With sham operated rats comparison, model control group SOD has reduction trend; With model control group comparison, treatment group has increased SOD trend; With model control group comparison, treatment group can obviously reduce MDA content (
p< 0.05).
CK, SOD, the comparison of MDA level in the each group of table 1 rat plasma
With sham operated rats comparison,
▼ p< 0.05,
▼ ▼ p< 0.01; With model control group comparison,
★ p< 0.05,
★ ★ p< 0.01.
Result of the test by table 2 can find out, with sham operated rats comparison, model control group rat heart infarct size obviously increase (
p< 0.01); With model control group comparison, treatment group infarct size significantly dwindle (
p< 0.01).
The comparison of the each group of table 2 rat myocardial infarction model rate
With sham operated rats comparison,
▼ p< 0.05,
▼ ▼ p< 0.01; With model control group comparison,
★ p< 0.05,
★ ★ p< 0.01.
Claims (6)
1. prevent and treat a pharmaceutical composition for acute myocardial infarction, it is characterized in that described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Pericarppium arachidis hypogaeae 42-60 part, Fructus Tritici Levis 42-60 part, stir-fry Semen Cassiae 16-25 part, Rhizoma Zingiberis 16-25 part, Fructus Arctii 25-38 part.
2. the pharmaceutical composition of control acute myocardial infarction according to claim 1, is characterized in that described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: Pericarppium arachidis hypogaeae 48-53 part, Fructus Tritici Levis 48-53 part, stir-fry Semen Cassiae 18-22 part, Rhizoma Zingiberis 18-22 part, Fructus Arctii 30-32 part.
3. the pharmaceutical composition of control acute myocardial infarction according to claim 2, is characterized in that described pharmaceutical composition is prepared from by the traditional Chinese medicinal material raw materials of following weight portion: 50 parts of Pericarppium arachidis hypogaeaes, 50 parts of Fructus Tritici Levis, 20 parts of Semen Cassiae of stir-fry, 20 parts of Rhizoma Zingiberiss, 30 parts of Fructus Arctiis.
4. the application of the compositions described in claim 1-3 any one in the medicine of preparation control acute myocardial infarction.
5. according to the application of claim 4, it is characterized in that: described medicine is oral formulations.
6. according to the application of claim 5, it is characterized in that: described oral formulations comprises oral liquid, tablet, capsule, granule.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410090935.3A CN103784934B (en) | 2014-03-13 | 2014-03-13 | A kind of pharmaceutical composition and application thereof preventing and treating acute myocardial infarction |
| CN201610043446.1A CN105617326A (en) | 2014-03-13 | 2014-03-13 | Method for preparing pharmaceutical composition for preventing and treating acute myocardial infarction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410090935.3A CN103784934B (en) | 2014-03-13 | 2014-03-13 | A kind of pharmaceutical composition and application thereof preventing and treating acute myocardial infarction |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610043446.1A Division CN105617326A (en) | 2014-03-13 | 2014-03-13 | Method for preparing pharmaceutical composition for preventing and treating acute myocardial infarction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103784934A true CN103784934A (en) | 2014-05-14 |
| CN103784934B CN103784934B (en) | 2016-03-09 |
Family
ID=50661271
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610043446.1A Withdrawn CN105617326A (en) | 2014-03-13 | 2014-03-13 | Method for preparing pharmaceutical composition for preventing and treating acute myocardial infarction |
| CN201410090935.3A Active CN103784934B (en) | 2014-03-13 | 2014-03-13 | A kind of pharmaceutical composition and application thereof preventing and treating acute myocardial infarction |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610043446.1A Withdrawn CN105617326A (en) | 2014-03-13 | 2014-03-13 | Method for preparing pharmaceutical composition for preventing and treating acute myocardial infarction |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105617326A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104888177A (en) * | 2015-06-30 | 2015-09-09 | 德州学院 | Heart qi deficiency type ischaemic myocardial infarction treatment medicine compound and preparation method thereof |
| CN104940597A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Chinese herbal composition used for treating myocardial infarction, and preparation method of Chinese herbal composition |
| CN104940279A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Application of Chinese herbal composition to preparation of medicine for treating myocardial infarction |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623258A (en) * | 2013-11-13 | 2014-03-12 | 青岛市市立医院 | Medicament composition for treating angina and application of medicament composition |
-
2014
- 2014-03-13 CN CN201610043446.1A patent/CN105617326A/en not_active Withdrawn
- 2014-03-13 CN CN201410090935.3A patent/CN103784934B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623258A (en) * | 2013-11-13 | 2014-03-12 | 青岛市市立医院 | Medicament composition for treating angina and application of medicament composition |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104888177A (en) * | 2015-06-30 | 2015-09-09 | 德州学院 | Heart qi deficiency type ischaemic myocardial infarction treatment medicine compound and preparation method thereof |
| CN104940597A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Chinese herbal composition used for treating myocardial infarction, and preparation method of Chinese herbal composition |
| CN104940279A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Application of Chinese herbal composition to preparation of medicine for treating myocardial infarction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105617326A (en) | 2016-06-01 |
| CN103784934B (en) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101209173B1 (en) | Method for preparing of samgyetang and samgyetang prepared by the method | |
| KR101501433B1 (en) | A composition for prevention and treatment of non-alcoholic fatty liver disease | |
| CN104186777A (en) | Health function tea and preparation method thereof | |
| JP2021008447A (en) | Health keeping product composition applicable to adult female, elderly, and sub-healthy people | |
| CN102640829B (en) | Tea paste with myocardial ischemia function improving function and preparation method of tea paste | |
| CN104286273A (en) | Application of dendrobium candidum and tea leaf product thereof | |
| KR100731160B1 (en) | Crude drugs composition for accelerating recovery of bone fracture | |
| CN103784934B (en) | A kind of pharmaceutical composition and application thereof preventing and treating acute myocardial infarction | |
| KR101446396B1 (en) | Processing method, manufacturing method of composition for gastritic and colitis, and composition thereof | |
| CN107519310A (en) | Improve Chinese medicine composition and preparation technology that energy suppresses growth of tumour cell function | |
| CN108570116B (en) | Pleurotus citrinopileatus polysaccharide, preparation method and medical application in preventing and treating diabetes | |
| KR20180079920A (en) | Composition for preventing, improving or treating hepatic fibrosis or liver cirrhosis comprising Cuscuta Semen extract | |
| CN105104626A (en) | Sweet dew brick tea composition and preparing method and application thereof | |
| CN110353146A (en) | A kind of formula of the dedicated mulberry leaf compound hypoglycemic solid beverage of diabetes patient | |
| CN105105165A (en) | Maca Yanchun yak meat jerky (slice) | |
| CN105028829A (en) | Preparing method of instant agilawood leaf tea | |
| CN108077485A (en) | A kind of blue or green money willow herbal tea and preparation method thereof | |
| CN107970355A (en) | A kind of composition for being used to treat coronary heart diseases and angina pectoris | |
| KR20030053417A (en) | Health food composition which contains Saururus chinensis Baill. and others | |
| CN110090249A (en) | Prevent and treat the Chinese medicine composition and the preparation method and application thereof of hypertension | |
| CN106306258A (en) | Tea capable of lowering blood pressure and preparation method of tea | |
| CN110237209A (en) | It is a kind of for treating the composition and preparation method thereof of depressive anxiety disease | |
| CN105055856B (en) | A kind of Tea Pigment Chinese medicine composition and its preparation method and application for treating cardiovascular and cerebrovascular disease | |
| CN105475581B (en) | A kind of roselle health-care bagged tea and preparation method thereof | |
| KR102515041B1 (en) | Health food using sprout ginseng and manufacturing method of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160206 Address after: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266000, Optics Valley Software Park, second floors Applicant after: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Applicant after: Zhang Shaohua Address before: 266200, No. seven, 179 village, Wenquan Town, Jimo, Shandong, Qingdao Applicant before: Cui Xinming |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160627 Address after: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266000, Optics Valley Software Park, second floors Patentee after: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Address before: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266000, Optics Valley Software Park, second floors Patentee before: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. Patentee before: Zhang Shaohua |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Shaohua Inventor after: Ding Ximing Inventor after: Lu Liqin Inventor before: Zhang Shaohua |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170524 Address after: 226200 No. 46 Industrial Park, Nanyang Town, Nantong, Jiangsu, Qidong Patentee after: Qidong planting valve factory Address before: Twenty-seventh, No. 396, Emei Mountain Road, Huangdao District, Shandong City, Qingdao Province, Qingdao 266000, Optics Valley Software Park, second floors Patentee before: QINGDAO HUAZHICAO MEDICAL TECHNOLOGY CO., LTD. |